Literature DB >> 32556512

Characteristics and prognosis of borderline ovarian tumors in pre and postmenopausal patients.

Ori Tal1, Hadas Ganer Herman2, Ohad Gluck2, Tally Levy2, Ram Kerner2, Jacob Bar2, Ron Sagiv2.   

Abstract

OBJECTIVE: To compare patient characteristics, imaging results, surgical management and prognosis of borderline ovarian tumors (BOT) between pre and postmenopausal patients.
MATERIALS AND METHODS: A retrospective cohort of all cases of histologically verified BOT between 1990-2018, comparing presentation, imaging, surgical procedures and recurrence. Patients were included in the postmenopausal group if they reported 12 months of amenorrhea with or without menopausal symptoms.
RESULTS: During this 28 year study period, 66 operations were performed in which BOT was confirmed. Postmenopausal patients were 37-89 years old and premenopausal patients 18-50 years old, with an average age of 63.9 ± 13.4 and 36.2 ± 8.4 years, respectively (p < 0.001). The majority of patients in both groups were diagnosed due to abdominal pain, followed by incidental diagnosis on routine ultrasound. Imaging and CA-125 levels upon presentation were similar. Almost sixty percent of postmenopausal and 26.3% of premenopausal patients underwent laparotomy (p = 0.01), while those who underwent laparoscopy were 35.7% and 60.5%, respectively (p = 0.03). Most postmenopausal patients underwent bilateral salpingo-oophorectomy (BSO), whereas premenopausal surgeries involved cystectomy. Nearly all study patients were diagnosed in stage one. Malignant transformation occurred in 7.1% of postmenopausal patients. No malignant transformation was found in premenopausal patients.
CONCLUSION: BOT's present similarly in pre and postmenopausal patients. Postmenopausal patients undergo more extensive surgery, and are diagnosed in early stage disease. Despite a tendency for a more conservative approach in premenopausal patients, prognosis is similar in both groups.

Entities:  

Keywords:  Borderline ovarian tumor; CA125; Menopause; Ultrasound

Mesh:

Year:  2020        PMID: 32556512     DOI: 10.1007/s00404-020-05652-w

Source DB:  PubMed          Journal:  Arch Gynecol Obstet        ISSN: 0932-0067            Impact factor:   2.344


  2 in total

1.  Recurrent implantation failure might be overestimated without PGT-A.

Authors:  Mauro Cozzolino
Journal:  Arch Gynecol Obstet       Date:  2020-09-01       Impact factor: 2.344

2.  Develop a nomogram to predict overall survival of patients with borderline ovarian tumors.

Authors:  Xiao-Qin Gong; Yan Zhang
Journal:  World J Clin Cases       Date:  2022-03-06       Impact factor: 1.337

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.